King buys Canadian rights to market EpiPen
This article was originally published in Clinica
Executive Summary
Bristol, Tennessee-based King Pharmaceuticals has acquired from distributor Allerex Laboratory exclusive rights to market and sell EpiPen, the epinephrine-filled auto-injector used as emergency treatment for severe anaphylaxis, in Canada.